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Abstract
Background: Right ventricular failure (RVF) following left ventricular assist device
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(LVAD) implantation is associated with worse outcomes. Prediction of RVF is diffi-
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cardiography (STE) showed promising results. We performed systematic review and
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cult with routine transthoracic echocardiography (TTE), while speckle-tracking echometa-analysis of published literature.
Methods: We queried multiple databases to compile articles reporting preoperative
or intraoperative right ventricle global longitudinal strain (RVGLS) or right ventricle
free wall strain (RVFWS) in LVAD recipients. The standard mean difference (SMD) in
RVGLS and RVFWS in patients with and without RVF postoperatively was pooled
using random-effects model.
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Results: Seventeen studies were included. Patients with RVF had significantly lower
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to −1.50; P: <.001) and −3.05 (95% CI: −4.11 to −1.99; P: <.001), respectively. The
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ysis, TTE-derived GLS and FWS were significantly lower in RVF patients as compared
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(95% CI: −4.11 to −1.99; P: <.001), respectively. There was no significant difference
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RVGLS and RVFWS as compared to non-RVF patients; SMD: 2.79 (95% CI: −4.07
pooled odds ratio (OR) for RVF per percentage increase of RVGLS and RVFWS were
1.10 (95 CI: 0.98–1.25) and 1.63 (95% CI 1.07–2.47), respectively. In a subgroup analto non-RVF patients; SMD of −3.97 (95% CI: −5.40 to −2.54; P: <.001) and −3.05
between RVF and non-RVF groups in TEE-derived RVGLS and RVFWS.
Conclusion: RVGLS and RVFWS were lower in patients who developed RVF as compared to non-RVF patients. In a subgroup analysis, TTE-derived RVGLS and RVFWS
were reduced in RVF patients as compared to non-RVF patients. This difference was
not reported with TEE.
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1 | I NTRO D U C TI O N

search was conducted using the following databases: MEDLINE,
EmCare, CINAHL, Cochrane Database, and Google Scholar. The

In the year 2019, there was 9000 LVAD implanted across the globe

following keywords and search terms were used: (“echocardiogra-

as an established therapy for patients with advanced heart failure

phy” AND “left ventricular assist device OR LVAD” AND “speckle-

(HF). With the comparable mortality outcomes to heart transplanta-

tracking echocardiography”, AND “right ventricle”). Search results

tion and the shortage of donor organs, the use of LVAD is projected

were limited to articles published in the English language. The

to continue to increase.1 Right ventricular failure (RVF) is a common

searched databases and number of titles screened are provided in

complication following LVAD implantation that complicates 20–25%

the Supplementary Appendix S1.

of cases and associated with increased morbidity and mortality
postoperatively. 2 Proposed mechanisms for RVF suggest acute increase in right-sided preload due to improved left ventricular output,

2.2 | Study selection and data extraction

leading to stretching of the right ventricular wall with subsequent
functional tricuspid regurgitation, and ultimately decreased right
2

To be eligible for inclusion, studies should be (a) reporting on adult

ventricular output. Studies have demonstrated that early prediction

patients ≥18 years of age undergoing LVAD implantation, (b) report-

of RVF and timely intervention often with biventricular mechanical

ing on the occurrence of RVF, and (c) reporting on preoperative and/

support (BiVAD) confer favorable outcomes.3 Hence, several predic-

or intraoperative two-dimensional echocardiography—with report

tive risk scores were modeled to assess the risk of RVF among LVAD

on GLS and/or FWS. RVF was defined as the need for right ventricu-

recepients.

4–7

However, the performance of these predictive scores

had not been consistent across studies6,7 and their validity had not
been well established in continuous-flow LVAD.4,5

lar assist device (RVAD), central venous pressure (CVP) >16 mm Hg,

cardiac index <2.3 L/min/m2, or the need for postoperative iono-

tropic support.15 We excluded case reports, review articles, editori-

The complexity of right ventricle (RV) anatomy and its loca-

als, and correspondences to the editor. Studies and those which did

tion in the chest obscure the ability to obtain detailed anatomical

not include GLS and/or FWS or did not report postoperative right

and functional evaluation in every patient. 2 While the longitudinal

ventricular function were excluded. Data were extracted by two

shortening of the RV can be estimated by assessing the tricuspid

independent investigators KB and MC into a predefined collection

annular plane systolic excursion (TAPSE), its discriminatory ability

sheet. All disagreements were resolved in consensus with a third re-

5

to predict RVF has been heterogeneous among studies. Speckle-

viewer (DR). Extracted data included baseline characteristics, defini-

tracking echocardiography (STE) is a novel imaging modality which

tion of RVF, occurrence of RVF, GLS, and FWS.

demonstrates promising results in predicting RVF after LVAD implantation.8 The region of interest (ROI) is delineated by speckles
and followed through the cardiac cycle.9,10 Correlation has been

2.3 | Quality assessment

well demonstrated with RV ejection fraction as measured by cardiac
magnetic resonance (CMR).11,12 RV assessment by STE can be either

The Newcastle–Ottawa Scale (NOS) was used to evaluate the qual-

for the entire RV, including the interventricular septum, or limited

ity of included studies.16 The authors generated a checklist for

to the RV free wall—which is considered a more focused and less

representativeness of included cohort, ascertainment of exposure,

biased assessment. Most published reports included small sample

comparability, and adequacy of follow-up as per the NOS. A maxi-

size, but with an overall common shared approach. To our knowl-

mum of 9 stars were awarded to each study, as determined by 2

edge, only one prior meta-analysis has evaluated the utility of RV

independent reviewers. Studies awarded ≥6 stars were considered

strain in predicting RVF; the analysis only included three studies and

moderate-to-high quality studies.16

13

was limited to TTE-derived FWS.

Thus, we performed a systematic

review and meta-analysis of published studies that investigated the
role of STE and longitudinal RV strain in predicting RVF following

2.4 | Statistical analysis

LVAD implantation.
Continuous data (eg, RVGLS and RVFWS) were pooled as a standard

2 | M E TH O DS
2.1 | Search strategy

mean difference (SMD) between RVF and non-RVF groups. Randomeffect model was adopted in all analyses. We used inverse variance
method with DerSimonian and Laird approach to calculate Tau2,
for continuous data. Odds ratio were pooled using inverse variance
method Paule–Mandel estimator of Tau2. Between-study hetero-

Our study protocol followed the recommendation of the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses

geneity was assessed using Q and I2 statistics. An I2 statistic <25%
indicates a low amount of heterogeneity and >50% indicates a high

(PRISMA) statement.14 We conducted an electronic search of the

heterogeneity.17 We explored sources of heterogeneity using sub-

literature to identify publications reporting on the predictive role

group analyses by subgrouping the studies based on (a) echocardiog-

of STE in postoperative RVF among LVAD recipients. Systematic

raphy modality (transthoracic vs transesophageal echocardiography)

|
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and (b) software used for image acquisition (EchoPAC software ver-

characteristics and LVAD types of study participants are provided

sus others). We assessed publication bias using Egger regression test

in Table 3. The population of the cohorts was male predominant, as

and funnel plots. Analyses were conducted using STATA 16 (State

the proportion of males was >70% in all studies. The type of LVAD

Corp LLC, College Station, Texas). A P-value < .05 was considered

device varied across the studies, including HeartMate II, HeartMate

statistically significant.

III, and HeartWare (Table 4). Five studies provided both the RVGLS
and RVFWS.8,21,28,29,33

3 | R E S U LT
Preliminary search yielded 1195 records and after duplicates re-

3.2 | Right ventricular global longitudinal Strain
(RVGLS)

moval, a total of records were identified for “title and abstract”
screening. Upon “title and abstract” screening, another 1037 records

RVGLS was reported in 11 studies (9 TTE and 2 TEE stud-

were excluded. Twenty-eight full-text articles were assessed for eli-

ies).8,20-23,27-29,31-33 The RVGLS was significantly reduced preop-

gibility and of those seventeen studies were included in our analysis.

eratively in the RVF group as compared to non-RVF group when

The flow diagram of the study is depicted in Figure 1.

analyzed for the whole cohort (TEE and TTE). The SMD between
the RVF and the non-RVF groups was −2.79 (95% CI: −4.07 to
−1.50; P-value < .001), I2 = 91.31%. When the TEE-derived RVGLS

3.1 | Study characteristics

was sub-analyzed, there was no statistically significant difference
in RVGLS between the two groups, with a SMD of −0.78 (95% CI:

Seventeen studies, with a total number of 1085 LVAD recipients,
fulfilled our inclusion criteria.8,13,18-32 Study characteristics and

−1.13 to −0.43; P-value = .54), I2 = 0.00%. Nonetheless, the TTEderived RVGLS remained significantly decreased in the RVF group

outcomes are summarized in Tables 1 and 2. Thirteen studies used

when analyzed separately, SMD of −3.37 (95% CI: −4.71 to −2.02;

transthoracic echocardiography (TTE) strain, while four studies uti-

P-value < .001), I2 = 83.57%. Forest plot for pooled SMD in RVGLS

19,22,23,26

lized transesophageal echocardiography (TEE).

The baseline

using TTE and TEE modalities is depicted in Figure 2. We pooled

Records idenfied through
database searching
(n = 1191)

Addional records idenfied
through other sources
(n =4)

Records aer duplicates removed
(n =1115)

Records screened
(n =1115)
Full-text arcles excluded,
with reasons
(n = 3)
1.

Full-text arcles assessed
for eligibility
(n =28)

2.
3.
4.

F I G U R E 1 PRISMA flowchart showing
the search strategy and studies selection
process

Studies included in
qualitave synthesis
(n =17)

1 outcome nonconsistent with RVF
5 no RV strain
reported
3 no RVF vs No RVF
group
2 review arcles

Studies included in
quantave synthesis
(meta-analysis)
(n =17)

Retrospective

Prospective

Retrospective

Retrospective

Retrospective

Retrospective

Prospective

Prospective

Retrospective

Prospective

Retrospective
cohort study

Prospective

Retrospective
study

Retrospective

Prospective

Prospective

Retrospective

Alfirevic, 2019

Assouie, 2015

Aymami, 2017

Beck, 2017

Bellavia, 2019

Boegershausen, 2017

Cameli, 2013

Cameli, 2015

Charisopoulou, 2018

Grant, 2012

Gumus, 2018

Kato, 2013

Magunia, 2018

Silverton, 2018

Wang, 2015

Kalogeropoulos, 2016

Ruiz-Cano, 2020

TTE

TTE

TTE

TEE

TEE

TTE

TTE and
TEE

TTE

TTE

TTE

TTE

TTE

TTE

TEE

TTE

TTE

TEE

Modality

EPIQ 7G

DICOM

Syngo Velocity
Vector Imaging,
(Siemens)

EchoInsight

TOMETEC
Image-Arena

GE EchoPAC

Not Reported

Syngo Velocity
Vector Imaging,
(Siemens)

Vivid 7 and
EchoPAC

GE EchoPAC

GE EchoPAC

GE EchoPAC

GE EchoPAC

Syngo US
Workplace

Philips IE 33 US
systems

QLAB CMQ,
Philips

Ultrasound Philips
platform

Software

80

38

39

100

26

68

57

117

70

19

10

54

64

57

158

42

86

Patients
Number (N)

26 (32.5%)

15 (39%)

11 (39%)

19 (19%)

5 (19.2%)

24 (35.3%)

20 (35%)

47 (40%)

14 (20%)

4 (16%)

3 (30%)

13 (24%)

8 (11%)

21(36.8%)

60 (38%)

24 (57%)

15 (17%)

RVF, n (%)

Patients with CF-LVAD

Patients with CF-LVAD

Patients with second-generation CF-LVAD

Systolic heart failure patients with elective
LVAD implantation.

Patients undergoing CF-LVAD implantation

Patients undergoing LVAD

Patients with LVAD as a bridge to
transplant.

Patients undergoing LVAD implantation

Patients who underwent CF-LVAD
implantation

Patients referred for LVAD therapy.

Patients referred for LVAD therapy.

Patient with CF-LVAD implantation at the
study site

Patients referred to HVAD implantation at
ISMETT and Papa Giovanni XXIII.

Patients with a nonpulsatile durable LVAD

Patients who underwent implantation of
CF-LVAD

Patients undergoing LVAD therapy

LVAD patients with TAD, strain, and TAPSE
measures available.

Inclusion criteria

RVF following LVAD implantation

RVF following LVAD implantation.

Death or implantation of an RVAD due
to acute RVF within 6 months of LVAD
implant.

RVF following LVAD implantation.

RVF following CF-LVAD implantation.

RVF following LVAD implantation.

RVF following LVAD implantation.

RVF following LVAD implantation.

RV failure requiring RVAD implantation
within 30 days.

RVF following LVAD implantation.

RVF following LVAD implantation.

RVF following CF-LVAD implantation.

RVF following LVAD implantation.

A composite of 6-month death, >14 d
inotropes, need for mechanical RV
support, or device thrombosis requiring
explant.

Early (<30 d) postoperative RV failure

RVF following LVAD implantation.

RVF occurring after LVAD implantation
(before hospital discharge).

Endpoints

|

Abbreviations: CF-LVAD = continuous-flow LVAD; HVAD = HeartWare ventricular assist device; LVAD = left ventricular assist device; RVF = right ventricular failure; TEE = transesophageal
echocardiography; TTE = transthoracic echocardiography.

Design

Characteristics and outcomes of studies included in the analysis

Study

TA B L E 1

4
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TA B L E 2

5

Definitions of right ventricular failure (RVF) across included studies

Study

RVF definition

Alfirevic, 2019

• The need for RVAD or prolonged (>14 d) intravenous inotropic or inhaled vasodilator medications after LVAD
implantation.
• Patients requiring RVAD owing to inability to separate from bypass during the LVAD procedure.

Assouie, 2015

• The need for placement of a temporary RVAD or the use of inotropic agents for 14 d.

Aymami, 2017

• Early (<30 d) RVF predefined according to the INTERMACS definition as sustained elevation of central venous
pressure > 16 mm Hg and the need for prolonged inotropes beyond 7 d, or the unplanned need for RVAD
implantation.

Beck, 2017

• Adverse events: A composite of one or more of the following: death within 6 mo, >14 d on inotropes, need for
mechanical RV support, or device thrombosis requiring explant.

Bellavia, 2019

• The need for intravenous inotropes for > 2 wk; persistent RV stroke work index (RVSW) < 4.0 g/m2; or nitric oxide
inhalation for > 48 h at any rotation speed or saline infusion; or presence of acute RVF when emergent/ urgent need
for mechanical RV support was considered mandatory.

Boegershausen, 2017

• The need for an RVAD or the requirement of inhaled nitric oxide or inotropic therapy for > 1 wk any time after LVAD
implantation in the presence of symptoms and signs of persistent RV dysfunction.

Cameli, 2013

• The postoperative need of intravenous inotrope support for > 14 d or of inhaled nitric oxide for > 48 h, or the need
for right-sided circulatory support or RVAD, or for hospital discharge with an intravenous inotrope.

Cameli, 2015

• The postoperative need of intravenous inotrope support for > 14 d or of inhaled nitric oxide for > 48 h, or the need
for right-sided circulatory support.

Charisopoulou, 2018

• RVAD implantation within 30 d

Grant, 2012

• The need for the placement of an RVAD, or the use of inotropic agents for > 14 d.

Gumus, 2018

• The need for RVAD, prolonged (>14 d) intravenous inotropic or inhaled vasodilator medications after LVAD
implantation, MAP < 55 mm Hg, or CVP or right atrial pressure > 16 mm Hg.

Kato, 2013

• The need for salvage RVAD, or persistent need for inotrope and/ or pulmonary vasodilator therapy 14 d after
surgery.

Magunia, 2018

• Prolonged inotropic support for > 14 d after LVAD implantation or consecutive implantation of RVAD.

Silverton, 2018

• 14 consecutive days of inotrope therapy or subsequent RVAD implantation.

Wang, 2015

• The need for continuous postoperative inotropic agents for > 14 d, pulmonary vasodilator use (inhaled nitric oxide)
>48 h, or right-sided mechanical support.

Kalogeropoulos, 2016

• Elevated CVP> 18 and CI < 2.0 L/min/m2, need for inhaled nitric oxide or inotropic support beyond 7 d, or the need
of RVAD

Ruiz-Cano, 2020

• Elevated CVP> 16, with CI < 2 L/min/m2, requiring RVAD implantation, or the need for inotropic therapy or inhaled
vasodilators beyond day 14

Abbreviations: CI = cardiac index; CVP = central venous pressure; LVAD = left ventricular assist device; RVAD = right ventricular assist device;
RVF = right ventricular failure.

odds ratio (OR) for RVF with percentage increase in RVGLS, which

Forest plot for pooled SMD in RVFWS using TTE and TEE modali-

was reported in 3 studies Ref.20,27,29 The OR was 1.10 (95 CI:

ties is depicted in Figure 3. The OR for RVF with percentage in-

0.98–1.25) (Supplementary appendix S1).

crease in FWS was reported in 3 studies, OR: 1.63, 95% CI 1.07–2.47
(Supplementary Appendix S1). 25,29,34

3.3 | Right ventricular free wall strain (RVFWS)

3.4 | Heterogeneity

RVFWS was reported in 12 studies (9 TTE and 3 TEE).8,19,21,22,2426,28-30,33,34

The RVFWS for the whole cohort (TEE and TTE) was

We further explored between-study heterogeneity using sub-

found to be significantly lower preoperatively in patients who suf-

group analysis based on the software use for image acquisition

fered RVF compared to non-RVF group; SMD: −2.75 (95% CI: −3.72

(EchoPAC software versus others). Subgroup analysis of studies that

to −1.79; P-value < .001), I2 = 88.08%. Upon subgroup analysis based

used EchoPAC software was performed for both the TTE-derived

on modality, there was no statistically significant difference in the

RVGLS and RVFWS. Five studies used EchoPAC to analyze the

TEE-derived RVFWS between RVF and non-RVF groups; SMD of

RVGLS strain,8,20,28,29,34 whereas four studies used EchoPAC to ana-

2

–1.81 (95% CI: −4.00 to 0.38; P-value = .07), I = 69.96%. However,

lyze the strain values for the RVFWS.8,28,29,34 In the studies using

the TTE-derived RVFWS was significantly higher in RVF patients;

EchoPAC, the pooled SMD in RVGLS between RVF and non-RVF

SMD of −3.05 (95% CI: −4.11 to −1.99; P-value < .001), I2 = 84.13%.

groups (Figure 4) was −3.71 (95% CI: −5.64 to −1.77; P-value = .04),

6
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Demographics (age and sex) and left ventricular assist device (LVAD) type across included studies
Age

Sex (male)

LVAD type

Study

Non-RVF

RVF

Non-RVF

RVF

Non-RVF

RVF

Alfirevic, 2019

58 ± 12

56 ± 14

57 (80%)

14 (93%)

• HeartMate II: 36 (50.7)
• HeartMate III: 13 (18.3)
• HeartWare: 22 (31.0%)

• HeartMate II: 7 (46.7%)
• HeartMate III: 4 (26.7%)
• HeartWare: 4 (26.7%)

Assouie, 2015

60 (48-69)

52 (43-61)

18 (100%)

21 (88%)

–

–

Aymami, 2017

56.6 ± 12.8

46.8 ± 15.5

70 (71%)

45 (90%)

–

–

Beck, 2017

51.0 ± 15.5

57.3 ± 10.5

32 (89%)

14 (67%)

• HeartMate II: 31 (86)
• HeartWare: 5 (14)

• HeartMate II :2 (10%)
• HeartWare :19 (90%)

Bellavia, 2019

59 ± 11

54 ± 13

51 (91%)

7 (88%)

–

–

Boegershausen, 2017

60.6 ± 7.6

63.2 ± 7.2

36 (88%)

10 (77%)

–

–

Cameli, 2013

66.4 (5.1)

65.8 ± 4.8

6 (86%)

3 (100%)

–

–

Cameli, 2015

–

–

–

–

–

–

Charisopoulou, 2018

48 ± 12

45 ± 11

50 (89%)

9 (64%)

• HeartMate III 4(10.8)

• HeartMate III 4 (20)

Grant, 2012

58 (47-65)

–

92 (79%)

–

–

–

Gumus, 2018

40.0 ± 15.0

39.8 ± 22.6

34 (92%)

13 (65%)

• HeartWare 21 (56.7)

• HeartWare: 7 (35%)

Kato, 2013

62.5 ± 12.4

62.8 ± 10.6

39 (89%)

22 (92%)

–

–

Magunia, 2018

64 ± 13

58 ± 30

19 (91%)

5 (100%)

• HeartMate II: 14 (66.7%)
• HeartMate III: 4 (19%)
• HeartWare 3: (14.3%)

• HeartMate II: 11 (20%)
• HeartMate III: 3 (60%)
• HeartWare: 1 (20%)

Silverton, 2018

60.6 ± 13.4

64 ± 11.2

71 (88%)

18 (95%)

•
•
•
•

•
•
•
•

Wang, 2015

56 ± 15

57 ± 16

22 (78%)

9 (82%)

–

–

Kalogeropoulos, 2016(
for the whole cohort)

51.8 + 13.5

–

25(61%)

• HeartMate II 20 (48.8)
• HeartWare 21 (51.2)

–

Ruiz-Cano, 2020

61 (55.2, 68)

61 (58.8, 68)

48 (89%)

24 (92%)

HeartMate II: 39 (48.1)
HeartMate III: 0 (0.0%)
HeartWare: 37 (45.7%)
Jarvik 2000:4 (4.9%)

HeartMate II: 8 (42.1%)
HeartMate III: 1 (5.3%)
HeartWare 8: (42.1%)
Jarvik 2000 2: (10.5%)

–

Abbreviation: RVF = right ventricular failure.

TA B L E 4

Quality assessment of included studies using the Newcastle–Ottawa Scale (NOS)
Selection (max of 4
stars)

Comparability (max
of 2 stars)

Outcome (max of 3
stars)

Total score (max
of 9)

Overall quality
Moderate-to-high

Alfirevic, 2019

****

*

***

8

Assouie, 2015

****

*

***

8

Moderate-to-high

Aymami, 2017

****

*

***

8

Moderate-to-high

Beck, 2017

***

*

***

7

Moderate-to-high

Bellavia, 2019

****

*

***

8

Moderate-to-high

Boegershausen, 2017

****

*

***

8

Moderate-to-high

Cameli, 2013

****

*

***

8

Moderate-to-high

Cameli, 2015

***

*

***

7

Moderate-to-high

Charisopoulou, 2018

***

*

***

7

Moderate-to-high

Grant, 2012

****

*

***

8

Moderate-to-high

Gumus, 2018

***

*

***

7

Moderate-to-high
Moderate-to-high

Kato, 2013

****

*

***

8

Magunia, 2018

****

*

***

8

Moderate-to-high

Silverton, 2018

****

*

***

8

Moderate-to-high

Wang, 2015

****

*

***

8

Moderate-to-high

Kalogeropoulos, 2016( for the
whole cohort)

****

*

***

8

Moderate-to-high

Ruiz-Cano, 2020

****

*

***

8

Moderate-to-high
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F I G U R E 2 Forest plot depicting pooled standard mean difference in right ventricular global longitudinal strain between right ventricular
failure and non–right ventricular failure groups, stratified by imaging modality (transesophageal echo (TEE) and transthoracic echo (TTE))

I2 = 61.69%. In EchoPAC studies, the SMD in RVFWS between RVF

I2 = 83.22%. We further analyzed the groups according to the in-

and non-RVF groups (Figure 5) was −4.48 (95% CI: −5.97 to −2.98;

clusion or exclusion of inhaled pulmonary vasodilators, that is,

P-value < .001), I2 = 0.00%.

nitric oxide (NO). The pooled SMD for the severe and acute severe RVF vs non-RVF in the inhaled NO group was −3.99 (95% CI

3.5 | Need for inotropes and/or inhaled vasodilators
beyond 14 days after surgery
We also performed a subgroup analysis for studies which included
patients with severe, defined as the need for inotropes and/or in-

−4.78 to −3.19; P-value < .001), I2 = 0.00%, while the SMD for the
group that excluded inhaled NO was −2.24 (95% CI −4.00 to −0.49;
P-value < .001), I2 = 92.33%, Figure 7.

3.6 | Quality assessment

haled vasodilators beyond 14 days after surgery, and acute severe
RVF defined the need for RVAD.15 The RVGLS was significantly re-

Quality assessment of included studies using the NOS tool demon-

duced in the severe RVF vs non-RVF, SMD −3.73 (95% CI −5.37 to

strated that all studies can be described to be “moderate-to-high” in

2

−2.0; P-value < .001), I = 63.91%, Figure 6.
Similarly, in the RVFWS group, the pooled SMD for severe and
acute severe RVF was −3.26 (95% CI −4.40 to −2.12; P-value < .001),

quality (Figure 7). Of a maximum of 9 starts that can be awarded, all
included studies were awarded either 7 or 8 stars. Detailed results
of quality assessment are exhibited in Table 4.

8
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F I G U R E 3 Forest plot depicting pooled standard mean difference in right ventricular free wall strain between right ventricular failure and
non–right ventricular failure groups, stratified by imaging modality (transesophageal echo (TEE) and transthoracic echo (TTE))

4 | D I S CU S S I O N

Complex hemodynamics and a multitude of variables factor in
the development of RVF following LVAD implantation.38 First, a clin-

Prognosis in patients with advanced HF is dismal, with a 1-year

ically and hemodynamically subtle RV dysfunction might have pre-

mortality rate exceeding 25% and 50% in patients with class III-IV

existed in many patients prior to LVAD implantation. This puts them

and class IV HF, respectively. 35,36 Nonetheless, data from the

at increased risk of apparent RVF postoperatively. In addition, RV

Interagency Registry for Mechanically Assisted Circulatory Support

stroke volume depends in part on the LV contraction through the

(INTERMACS) have shown a promising 1-year survival rate of 80%

interventricular septum, a phenomenon called “interventricular de-

With such favorable outcomes, LVAD

pendence”.15 Improved LV output after LVAD implantation leads to

implantation has become the standard of care among patients with

LV decompression and leftward shift of the interventricular septum.

advanced HF—especially in the face of shortage of donor organs

This would disrupt the normal mechanics of the RV. Furthermore,

required for heart transplant. Yet, survival post-LVAD implantation

fluids and blood products transfusion peri-operatively might lead to

can be significantly impacted by RVF—the most common complica-

RV distention and exacerbation of RVF.18,30 An intraoperative injury

tion following LVAD implant, occurring in 20-25% of cases. Further,

is also a potential contributor that may worsen RV function.39

among LVAD recipients.

37

severe RVF necessitating additional mechanical support (eg, RVAD)
is reported to occur in about 15% of cases.6

In this meta-analysis of observational studies of 1085 patients,
we investigated the role of RV strain analysis in predicting RVF in

|
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F I G U R E 4 Forest plot depicting pooled standard mean difference in right ventricular global longitudinal strain between right ventricular
failure and non–right ventricular failure groups, in studies using EchoPAC software, in transthoracic echocardiogram

F I G U R E 5 Forest plot depicting pooled standard mean difference in right ventricular free wall strain between right ventricular failure and
non–right ventricular failure groups, in studies using EchoPAC software, in transthoracic echocardiogram

LVAD recipients. The main findings of the study were as follows: (a)

dependency. 23,40 Muraru et al showed that inclusion of interventric-

TTE-derived FWS and RVGLS were significantly lower in patients

ular septum in strain analysis yields significantly different strain val-

who suffered RVF following LVAD implantation, and (b) TEE-derived

ues from the value from analyzing RV free wall alone. Moreover, in

RVFWS and RVGLS were not significantly different between LVAD

their study, RVGLS, as compared to RVFWS, correlated better with

recipients who developed RVF and those who did not. However, the

pulmonary artery systolic pressure.41 The RVFWS as interpreted

second finding should be interpreted cautiously in light of the limited

from the OR was predictive of postoperative RVF. However, GLS as

number of included studies assessing TEE utility.

interpreted from the OR was not predictive of postoperative RVF.

The TTE-derived RVFWS was significantly higher in the RVF
group postoperatively. Speckle tracking carries the advantage of

These results, however, should be interpreted with caution, as only
three studies were used to pool these odds ratio. 20,27,29

angle-independent assessment of myocardial movement and is

The European Association of Cardiovascular Imaging (EACVI)/the

sensitive to subendocardial damage, which produces the strain. 23

American Society of Echocardiography (ASE) task force recommends

However, it can be affected by poor imaging, 25 previous cardiac

reporting the RV longitudinal strain as the RV free wall deformation

surgery due to tethering of the RV to the sternum, 24 and load

using the focused RV apical four-chamber view. They leave it “optional”

10
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F I G U R E 6 Forest plot showing pooled standard mean difference in transthoracic echocardiogram–derived right ventricular global
longitudinal strain in severe and acute severe right ventricular failure

F I G U R E 7 Forest plot showing pooled standard mean difference in transthoracic echocardiogram–derived right ventricular free wall
strain in severe and acute severe right ventricular failure, stratified using inhaled vasodilators

|
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to report the four-chamber global RV longitudinal strain, which would

and it evaluates the utility of using both RVFWS and RVGLS in pre-

include the interventricular septum, as it contributes to a lesser extent

dicting RVF after LVAD implantation. It also includes studies that

to the RV function.42 However, due to altered unloading conditions

performed TTE- and TEE-derived assessment. Furthermore, the het-

and septal mechanics in LVAD recipients, the role of the interventricu-

erogeneity was addressed and resolved in our study which increases

lar septum is more prominent and crucial to maintain RV function fol-

the validity of our results.

2

lowing implantation. Therefore, it would be reasonable to include the

This meta-analysis has certain limitations. First, it includes stud-

interventricular septum in measuring the RV longitudinal strain. This

ies with retrospective design, that could have excluded potential

meta-analysis supports this conclusion as GLS was predictive for RVF.

participants due to poor image quality. This could have introduced

Studies have shown variable correlation between TTE- and TEE-

a selection bias. Second, lack of a standardized RVF definition may

43-45

Marucci et al described “moderate” correlation for

have impacted the reported incidence and severity outcomes. Third,

global strain and “poor” correlation for regional stain for the left ven-

derived strains.

use of modalities (TTE and TEE) with different platforms for image

tricle in anesthetized patients.43 On the other hand, Kurt et al demon-

acquisition and being interpreted by different personnel could have

strated “good” correlation in healthy subjects not undergoing surgery.45

introduced measurement and observer bias, respectively.

Generally, speckle-tracking quality is dependent on temporal and spatial resolution.41 The higher frame rate provided by TEE results in a
different temporal resolution than that of TTE. And upon adjustment

5 | CO N C LU S I O N

of image sector to obtain a similar frame rate, the spatial resolution
gets affected which in turn affects the accuracy of delineation of the

RVGLS and RVFWS of the right ventricle assessed by STE were

endocardium.34 Furthermore, mechanical ventilation increases the RV

lower in patients developing RVF as compared to non-RVF patients.

afterload due to increased intra-thoracic pressure,46 hence decreasing

Further subgroup analysis indicated that TTE-derived GLS and FWS

the strain values. It is hard to draw accurate conclusion about TEE-

were associated with lower value in RVF patients as compared to

derived strain given the small number in our analysis.

non-RVF patients. This difference was not reported with TEE. More

Five studies reported cutoffs for predicting postoperative RVF;
−9.6, −10.5, −12.7, −14.4, and −15.5, respectively. 20,25,29,30,33 This

studies are needed to specify a strain cutoff value that can reliably
predict the adverse outcome of RVF.

variability might be attributed to the different methodologies used
to evaluate the strain, and the definitions of RVF used in individual

DATA AVA I L A B I L I T Y S TAT E M E N T

studies (Table 2). The INTERMACS registry defined mild RVF as el-
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different RVF definitions, and this may have affected the RVF reporting rate and contributed to between-study heterogeneity. To
test this hypothesis, we performed a subgroup analysis of studies
that included patients with severe and acute severe RVF as previously defined.15 Both the RVGLS and RVFWS remained significantly
reduced in the severe RVF group; however, the heterogeneity remained significant. In the RVFWS group, we further sub-stratified
according to inhaled pulmonary vasodilators use, which eliminated
the heterogeneity.
In addition to the variations in RVF definitions, heterogeneity
can be explained by the methodologies of obtaining the strain values. Subgroup analysis of TEE and TTE groups did reduce heterogeneity; however, it remained moderate-to-high in the TTE group.
Upon analyzing the studies that used EchoPAC software separately,
heterogeneity was completely eliminated (I2 = 0.00%) in the RVFWS
group. However, the results were less robust in the RVGLS group.
To our knowledge, only one meta-analysis has evaluated the utility of RV strain in predicting RVF.13 It only included 3 studies with reported RV FWS using TTE-derived assessment, and the outcome was
marginally significant with high heterogeneity. 20,28,30 The current
meta-analysis includes 17 studies with a total of 1085 participants,
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